Score Overview
Explore the 2021 public Archive ranking →
Biogen Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 1.71B to $ 9.81B and net income grew from $ 160M to $ 1.29B. Revenue increased in 15 of those 20 years; net income in 14.
Across Biogen Inc's full reported history, from 1991 to 2025, revenue grew from $ 61M to $ 9.81B and net income grew from $ 7M to $ 1.29B. Revenue increased in 77% of the years measured; net income in 69%.
Biogen Inc currently holds a 20-year HDB Score of 5.7 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-01 | $ 216.04 | — |
1 Year2025-08-29 | $ 132.22 | 63.39% |
5 Years2021-09-01 | $ 338.24 | -36.13% |
10 Years2016-09-01 | $ 306.03 | -29.41% |
20 Years2006-09-01 | $ 44.25 | 388.23% |
30 Years1996-08-30 | $ 3.90 | 55x |
| Period | Last Price2026-09-01 | 1 Year2025-08-29 | 5 Years2021-09-01 | 10 Years2016-09-01 | 20 Years2006-09-01 | 30 Years1996-08-30 |
|---|---|---|---|---|---|---|
| Price | $ 216.04 | $ 132.22 | $ 338.24 | $ 306.03 | $ 44.25 | $ 3.90 |
| Return | — | 63.39% | -36.13% | -29.41% | 388.23% | 55x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 9.94B | $ 835M | $ 1.28B |
| 2025 | $ 9.81B | $ 1.29B | $ 3.81B |
| 2024 | $ 9.67B | $ 1.63B | $ 2.37B |
| 2023 | $ 9.83B | $ 1.16B | $ 1.04B |
| 2022 | $ 10.17B | $ 3.04B | $ 4.89B |
| 2021 | $ 10.98B | $ 1.55B | $ 3.80B |
| 2020 | $ 13.44B | $ 4.00B | $ 2.61B |
| 2019 | $ 14.37B | $ 5.88B | $ 4.47B |
| 2018 | $ 13.45B | $ 4.43B | $ 3.53B |
| 2017 | $ 12.27B | $ 2.53B | $ 3.68B |
| 2016 | $ 11.44B | $ 3.70B | $ 4.89B |
| 2015 | $ 10.76B | $ 3.54B | $ 3.42B |
| 2014 | $ 9.70B | $ 2.93B | $ 1.84B |
| 2013 | $ 6.93B | $ 1.86B | $ 1.22B |
| 2012 | $ 5.51B | $ 1.38B | $ 1.70B |
| 2011 | $ 5.04B | $ 1.23B | $ 1.69B |
| 2010 | $ 4.71B | $ 1.00B | $ 1.20B |
| 2009 | $ 4.37B | $ 970M | $ 1.26B |
| 2008 | $ 4.09B | $ 783M | $ 1.37B |
| 2007 | $ 3.17B | $ 638M | $ 1.18B |
| 2006 | $ 2.68B | $ 217M | $ 902M |
| 2005 | $ 1.71B | $ 160M | $ 850M |
| 2004 | $ 1.59B | $ 25M | $ 1.05B |
| 2003 | $ 186M | -$ 875M | $ 835M |
| 2002 | $ 404M | $ 148M | $ 867M |
| 2001 | $ 1.04B | $ 272M | $ 798M |
| 2000 | $ 925M | $ 333M | $ 682M |
| 1999 | $ 794M | $ 220M | $ 654M |
| 1998 | $ 557M | $ 138M | $ 516M |
| 1997 | $ 434M | $ 89M | $ 440M |
| 1996 | $ 277M | $ 40M | $ 321M |
| 1995 | $ 151M | $ 5M | $ 307M |
| 1994 | $ 156M | -$ 4M | $ 267M |
| 1993 | $ 136M | $ 32M | $ 74M |
| 1992 | $ 123M | $ 38M | $ 85M |
| IPO1991 | $ 61M | $ 7M | $ 56M |
Where Biogen Inc has ranked, year by year
Each point is that year's ranking on ten years of fundamentals, as a share of every company we could rank at the time. Higher is better. We show the share rather than the place because the number of companies grows — 611 in 2002, 2,060 in 2021 — so the same place means something different at either end.
Reached the top 50 on HDB Score in 7 years, the longest run being 7 in a row — but not in 2021.
2002: 18.2% · 2021: 5.7% · free through 2021 · longest runs
See where BIIB ranks today
You're looking at Biogen Inc's public company record. Membership adds the current comparative layer and continues its ranking history through recent years.
- Current market-wide rankings across 3,839 covered companies
- See where Biogen Inc ranks today
- Complete current Score Views across every period
- Current Tenure and recent Archive years
- Portfolio and member features
$99/year $149 founding price
Become a Member30-day money-back guarantee.
